Instrument Inactif

Communiqués MELA Sciences Inc Nasdaq

Actions

US55277R1005

Equipement et technologie médicale avancés

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

28/07	STRATA Skin Sciences, Inc. annonce un changement à la direction générale	CI
18/05	STRATA Skin Sciences met en avant une étude clinique confirmant la supériorité du laser excimer XTRAC combiné aux inhibiteurs de JAK dans le traitement du vitiligo pédiatrique	CI

Communiqués

28/07	STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer	AQ
25/06	STRATA Skin Sciences : 06/25/2026 STRATA Skin Sciences Announces Exclusive Distribution Partnership with EKPAC Healthcare to Reestablish XTRAC® Leadership in China	PU
18/05	STRATA Skin Sciences : 05/18/2026 New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo	PU
18/05	New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo	AQ
19/02	STRATA Skin Sciences Confirms Nasdaq Delisting	AQ
18/02	Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser	AQ
17/02	STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis	AQ
09/12	STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico	AQ
13/11	STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update	AQ
06/11	STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion	AQ
05/11	STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update	AQ
28/10/25	STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements	AQ
20/10/25	STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek	AQ
14/10/25	Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides	AQ
03/10/25	Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis	AQ
30/09/25	STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis	AQ
22/09/25	New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach	AQ
04/09/25	STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering	AQ
04/09/25	STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements	AQ
03/09/25	STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules	AQ
02/09/25	STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
02/09/25	STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions	AQ
13/08/25	STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update	AQ
07/08/25	STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients	AQ
31/07/25	STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update	AQ